The FDA has approved Amgen’s blockbuster Otezla (apremilast) as a treatment for adults with plaque psoriasis of any severity, making it the first oral therapy cleared for that indication. Source:…
In a purchase aimed at broadening its portfolio of cancer therapies, Sanofi is acquiring San Francisco, Calif.-based Amunix Pharmaceuticals for $1 billion. Source: Drug Industry Daily
A range of drugs critical to patient care are slipping into shortage. Source: Drug Industry Daily
In an unusual bid to trim costs and win prescriber and payer support, Biogen has cut the price of Aduhelm in half. Source: Drug Industry Daily
AbbVie is pushing the International Trade Commission (ITC) to prevent Iceland-based biosimilar developer Alvotech from marketing its biosimilar candidate to AbbVie's blockbuster Humira (adalimumab). Source: Drug Industry Daily
The FDA has placed a partial clinical hold on Bluebird Bio’s gene therapy for sickle cell disease (SCD), lovotibeglogene autotemcel (lovo-cel), for trial participants under the age of 18 after…
The FDA plans to resume unannounced onsite inspections in India and China shortly after the New Year. Source: Drug Industry Daily
Amid an ongoing dispute with the National Institutes of Health (NIH) over who exactly invented the mRNA sequence of Moderna’s COVID-19 vaccine, the company is hitting the pause button on…
Ligelizumab, Novartis’ investigational anti-IgE antibody, didn’t stand up to the company’s established blockbuster omalizumab in a pair of phase 3 studies in patients with chronic spontaneous urticaria (CSU). Source: Drug…
A federal judge has overturned a $4.5 billion settlement that protected members of the Sackler family, owners of Purdue Pharma, the maker of OxyContin. Source: Drug Industry Daily